Is DMAA stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Drugs Made In America Acquisition Corp. Ordinary Shares has a Smart Value Score of 32/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is —.

Is Drugs Made In America Acquisition Corp. Ordinary Shares financially healthy?

Drugs Made In America Acquisition Corp. Ordinary Shares's Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of — places it in the —.

DMAA

Drugs Made In America Acquisition Corp. Ordinary Shares

NASDAQ: DMAA · FINANCIAL SERVICES · SHELL COMPANIES

$10.53

-0.28% today

Updated 2026-04-30

Market cap

$355.55M

P/E ratio

55.50

P/S ratio

—

EPS (TTM)

$0.19

Dividend yield

—

52W range

$10 – $11

Volume

0.2M

Market cap

$355.55M

P/E ratio

55.50

P/S ratio

—

EPS (TTM)

$0.19

Dividend yield

—

52W range

$10 – $11

Volume

0.2M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

4.0

Quality

3.5

Profitability

4.0

Valuation

2/9

Piotroski F-Score

Weak

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$—

—

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Piotroski 2/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-125180.00

- P/E 55.50x — expensive valuation

Key financials

Revenue Net Income Free Cash Flow

Metric	2024	2025	TTM
Revenue	—	$0.00	—
Net income	$-479.00	$5.94M	$212958.00
EPS	—	—	$0.19
Free cash flow	$-172270.00	$-539187.00	$-125180.00
Profit margin	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
DMAA	$355.55M	32	4.3	3.5	4.0	4.0	—	Avoid
BRK-A	$1.01T	53	3.3	7.5	5.0	8.0	—	Buy
BRK-B	$1.01T	54	3.3	7.5	5.0	8.0	—	Buy
JPM	$844.23B	73	8.0	8.0	5.7	5.5	—	Strong Buy
V	$596.57B	68	7.3	10.0	5.0	5.5	—	Strong Buy
MA	$449.94B	70	8.0	10.0	4.3	6.0	—	Strong Buy

Smart narrative

Drugs Made In America Acquisition Corp. Ordinary Shares trades at $10.53. representing a P/E of 55.50x trailing earnings. Our Smart Value Score of 32/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score.

Frequently asked questions

What is Drugs Made In America Acquisition Corp. Ordinary Shares's stock price?

Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) trades at $10.53.

Is Drugs Made In America Acquisition Corp. Ordinary Shares overvalued?

Smart Value Score 32/100 (Grade F, Strong Sell).

What is the price target of Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA)?

The analyst target price is $—, representing NaN% downside from the current price of $10.53.

Piotroski F-Score?

2/9 — weak financial health.

Company info

SectorFINANCIAL SERVICES

IndustrySHELL COMPANIES

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE—

Beta—

50D MA$10.49

200D MA$10.36

Shares out0.03B

Float0.03B

Short ratio—

Avg volume0.2M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

DMAA vs BRK-A →DMAA vs BRK-B →DMAA vs JPM →Stock screener →